SAFESKIN FIRST QUARTER SALES STRETCH 52% TO $17.5 MIL.; STERIS SYSTEM I AND STERIS 20 PRODUCTS HELP PUSH FISCAL YEAR 1994 SALES UP 71.9% TO $45.8 MIL.
This article was originally published in The Gray Sheet
Executive Summary
Hypoallergenic disposable latex glove firm Safeskin's first quarter 1994 sales sailed ahead 52% to $17.5 mil., pushing earnings up 22.6% to $2.8 mil. The growth stemmed from "strong market demand resulting from safety concerns about the spread of infectious disease, a continued shift in the market place towards powder-free gloves," and "pricing stability" for "premium-quality gloves," the firm said.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.